Please assess the completion status of the following clinical trial:

Trial Title: rhTSH, Thyroid Size, and Radioiodine Therapy in Benign Goiter

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers with an intact thyroid gland~* Patients with nontoxic/subtoxic nodular goiter confirmed by ultrasonography~* Patients with toxic nodular goiter~* Patients with Graves' disease~Exclusion Criteria:~* Treatment with drugs that alter thyroid function or size (the last 3 months prior to inclusion)~* Prior 131I treatment~* Alcohol, medicine or drug abuse~* Pregnancy or lactation~* No safe contraception~* Participation in another clinical trial~* Allergic reaction towards rhTSH~* Fine needle biopsy without valid diagnostic criteria for benign disease~* Suspicion of malignancy, increased ionized serum calcium and/or serum calcitonin~* Incontinence~* Physically or psychic condition that hinders corporation~* Ischemic attack up till 3 months before inclusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).